Evaluation of cardiac perfusion, structure and function in chronic liver and kidney disease

Evaluation of cardiac perfusion, structure and function in chronic liver and kidney disease: A cross-sectional observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN16005265

Enrollment

Registered

2014-08-19

Start date

2014-07-07

Completion date

Unknown

Last updated

2017-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease as result of chronic liver and chronic kidney disease Circulatory System

Interventions

1. MRI scan 2. Finometry 3. Thoracic bioimpedance 4. Skin autofluorescence 5. Blood samples 6. Applanation tonometry

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age above 18 and below 65 years 2. Able to give informed consent And either: 3. CKD Stage 3b (eGFR> 30 and <44 ml/min) or 4. Compensated Cirrhotic Liver Disease proven radiologically or on biopsy

Exclusion criteria

Exclusion criteria: 1. Known cardiac disease- previous myocardial infarction, angina, arrhythmias including AF, cardiac surgery, myocarditis, pericarditis or other non-specified cardiac conditions 2. Taking beta blockers, calcium channel blockers or other rate/rhythm controlling medication 3. Unstable CKD ? AKI Stage 1 or more or other unplanned hospital admission relating to their kidney disease in the last 30 days 4. Unstable CLD ? Clinical decompensation or other unplanned hospital admission relating to their liver disease in the last 30 days 5. For liver patients ? previous Transjugular Portosystemic Shunt (TIPSS) insertion 6. Pregnant, breastfeeding or intending pregnancy 7. Unable to give consent or understand written information 8. Contraindications to MRI ? pacemaker, metallic fragments or implants, known claustrophobia 9. Inability to sustain 20 minutes of light exercise 10. Diabetes

Design outcomes

Primary

Measure	Time frame
Myocardial perfusion as measured by Cardiac ASL MRI in ml/min/100g	—

Secondary

Measure	Time frame
1. Cardiac strain and architecture as measured by PC-MRI 2. Thoracic bioreactance 3. AGE measurement 4. Pulse wave velocity 5. Non-invasive haemodynamics (BP, CO, SVR) 6. Baroreceptor sensitivity 7. Echocardiographic measure of ejection fraction, heart volumes 8. Serum markers of cardiac damage, endotoxin levels, renal, liver function, clotting, full blood count	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026